1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

Apply for a research grant from the Mesothelioma Applied Research Foundation

2023 Grant Cycle

Thank you for your interest in applying for a mesothelioma research grant from the Mesothelioma Applied Research Foundation for the 2023 grant cycle. Our research grant program offers $100,000 grants for two years ($50,000 per year).

  • The pre-application LOI (Letter of Intent) submission period opens Wednesday, September 27.
  • The LOI deadline is at 11:59 PM ET on Friday, November 17, 2023.

Who Can Apply:

  • Investigators who have a doctoral-level degree and a full-time faculty position or equivalent at a college, university, medical school, or eligible not-for-profit research organization globally.
  • Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.

Additional information to be included in the LOI:

  • All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2023 Areas of Interest (listed below).
  • All projects must be feasible within the timeline and budgetary constraints of the current LOI.
  • All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.

Areas of Interest 2023 (not listed in order of priority):

  • Novel therapies for mesothelioma for both pleural and peritoneal, especially targeted therapies, combination immunotherapy, cellular therapy, and virotherapy.
  • Health-related quality of life assessment incorporating the social determinants of health (SDOH) specific to mesothelioma patient care, side effect management, mental health care impact on patient and/or caregiver outcomes, and other related topics.
  • Novel strategies for screening and early detection.
  • Novel strategies for risk assessment and prognosis stratification.
  • Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection, and management).
  • Improving personalization of therapies (gender and racial differences, targeted therapies, and predictive biomarkers).
  • Mechanisms of treatment resistance/failure.
  • Mesothelioma biology and etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment).

For questions, please contact Nicole Yost at [email protected] or 703-879-3797.

Contact Us